Polyrizon Secures All U.S. Clinical Sites for NASARIX Allergy Study…

Event summary

Polyrizon has finalized contracts with all five U.S. clinical sites for its NASARIX™ first-in-human allergy study.
The study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis.
The study aims to enroll up to 120 randomized patients, with subjects assigned in a 1:1 ratio to receive either NASARIX™ or an isotonic saline nasal spray control.
Patient enrollment is planned to coincide with relevant allergy seasons, with local pollen counts and weather conditions monitored to assess airborne allergen exposure.

The big picture

Polyrizon's completion of clinical site contracts marks a critical operational milestone in the development of NASARIX™, a non-drug approach for managing seasonal allergic rhinitis. The study's design, focusing on real-world allergen exposure, positions it to generate robust efficacy and safety data. Success in this phase could accelerate Polyrizon's pathway to commercialization in a competitive allergy treatment market.

What we're watching

Study Execution: The pace at which Polyrizon advances patient pre-screening and enrollment activities will determine the timeline for initial study results.
Seasonal Timing: Whether Polyrizon can effectively align patient enrollment with peak allergy seasons will impact the study's real-world relevance.
Regulatory Pathway: How the outcomes of this first-in-human study will position NASARIX™ for subsequent clinical phases and potential market approval.